Geron Co. (NASDAQ:GERN) Given Average Rating of “Buy” by Analysts

Shares of Geron Co. (NASDAQ:GERN) have earned a consensus rating of “Buy” from the eleven analysts that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $7.15.

A number of research analysts recently issued reports on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 price objective on shares of Geron in a report on Friday, December 13th. Leerink Partnrs upgraded shares of Geron to a “strong-buy” rating in a report on Monday, September 9th. HC Wainwright restated a “buy” rating and issued a $9.00 price objective on shares of Geron in a report on Tuesday, December 10th. Barclays upgraded shares of Geron to a “strong-buy” rating in a research report on Friday, November 29th. Finally, Scotiabank assumed coverage on Geron in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $6.00 price target on the stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. National Bank of Canada FI boosted its stake in shares of Geron by 1,200.0% in the 2nd quarter. National Bank of Canada FI now owns 6,500 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 6,000 shares during the last quarter. Readystate Asset Management LP bought a new position in Geron during the third quarter worth about $58,000. Rovin Capital UT ADV purchased a new position in Geron in the 3rd quarter valued at approximately $62,000. CIBC Asset Management Inc grew its position in shares of Geron by 32.7% in the second quarter. CIBC Asset Management Inc now owns 15,438 shares of the biopharmaceutical company’s stock valued at $65,000 after purchasing an additional 3,805 shares in the last quarter. Finally, Empowered Funds LLC purchased a new stake in shares of Geron in the third quarter worth about $67,000. Institutional investors own 73.71% of the company’s stock.

Geron Stock Down 1.2 %

Shares of GERN opened at $3.30 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89. Geron has a 52 week low of $1.64 and a 52 week high of $5.34. The stock has a market capitalization of $1.99 billion, a price-to-earnings ratio of -10.31 and a beta of 0.51. The stock has a fifty day moving average of $3.95 and a 200-day moving average of $4.33.

Geron (NASDAQ:GERN) last posted its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.05. The firm had revenue of $28.27 million during the quarter, compared to the consensus estimate of $18.97 million. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The business’s quarterly revenue was up 17138.4% on a year-over-year basis. During the same period last year, the company earned ($0.08) earnings per share. As a group, sell-side analysts anticipate that Geron will post -0.25 earnings per share for the current fiscal year.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.